StreetInsider.com News Articles

William Blair on Cullinan Oncology Inc. (CGEM): 'We continue to see multiple opportunities for upside to Cullinan shares'

Wed, 10 Jun 2026 16:14:57 -0400

William Blair analyst Matt Phipps reiterated an Outperform rating on Cullinan Oncology Inc. (NASDAQ: CGEM).

The analyst comments "On Wednesday, June 10, Cullinan hosted an Immunology Day event in New York City. Management presented additional data points from the Phase I trials of CLN-978 (CD19 x CD3 TCE) in systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) following initial results recently presented at EULAR (see our note), including first efficacy data from repeat-dosing cohorts in the RA study and first safety data from the repeat-dosing cohorts in the SLE study. Management also disclosed initial data for velinotamig (BCMA x CD3 TCE,

Cullinan Oncology Inc. (CGEM) PT Raised to $46 at Clear Street

Wed, 10 Jun 2026 16:10:17 -0400

Clear Street analyst Kaveri Pohlman raised the price target on Cullinan Oncology Inc. (NASDAQ: CGEM) to $46.00 (from $33.00) while maintaining a Buy rating.

Cullinan Therapeutics reports clinical trial data for autoimmune treatments

Wed, 10 Jun 2026 07:30:34 -0400

Cullinan Therapeutics Inc. (NASDAQ: CGEM) reported clinical data for two T cell engager therapies targeting autoimmune diseases. The Cambridge, Massachusetts-based biopharmaceutical company presented results from ongoing Phase 1 trials of CLN-978 for rheumatoid arthritis and systemic lupus erythematosus, and initial data for velinotamig in lupus patients.

In the OUTRACE rheumatoid arthritis trial, CLN-978 achieved clinical remission in one heavily pre-treated patient who had been refractory to rituximab. The patient's DAS28-ESR disease score decreased from 4.0 at baseline to 2.2 at week 4, maintained through week 8. The treatment was associated with rapid reduction in rheumatoid arthritis-related autoantibodies.

For systemic lupus erythematosus patients

Cullinan Therapeutics reports clinical trial data for autoimmune treatments

Wed, 10 Jun 2026 07:30:34 -0400

For systemic lupus erythematosus patients

Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases

Wed, 10 Jun 2026 07:30:00 -0400

CLN-978 (CD19 TCE) EULAR data demonstrated potential for immune reset, including remissions, in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA)

CLN-978 data from the first RA multi-dose regimen cohort demonstrated robust efficacy, including clinical remission in a poly-refractory patient, with a favorable safety profile

Initial velinotamig (BCMA TCE) data show promising clinical activity, including complete renal responses in lupus nephritis, supporting potential in plasma cell–driven autoimmune diseases

Complementary T cell engager portfolio unlocks broad commercial opportunity across B cell–driven and autoantibody-mediated diseases

Management to host Immunology Day event

Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases

Wed, 10 Jun 2026 07:30:00 -0400

CLN-978 (CD19 TCE) EULAR data demonstrated potential for immune reset, including remissions, in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA)

CLN-978 data from the first RA multi-dose regimen cohort demonstrated robust efficacy, including clinical remission in a poly-refractory patient, with a favorable safety profile

Initial velinotamig (BCMA TCE) data show promising clinical activity, including complete renal responses in lupus nephritis, supporting potential in plasma cell–driven autoimmune diseases

Complementary T cell engager portfolio unlocks broad commercial opportunity across B cell–driven and autoantibody-mediated diseases

Management to host Immunology Day event

Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases

Wed, 10 Jun 2026 07:30:00 -0400

CLN-978 (CD19 TCE) EULAR data demonstrated potential for immune reset, including remissions, in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA)

CLN-978 data from the first RA multi-dose regimen cohort demonstrated robust efficacy, including clinical remission in a poly-refractory patient, with a favorable safety profile

Initial velinotamig (BCMA TCE) data show promising clinical activity, including complete renal responses in lupus nephritis, supporting potential in plasma cell–driven autoimmune diseases

Complementary T cell engager portfolio unlocks broad commercial opportunity across B cell–driven and autoantibody-mediated diseases

Management to host Immunology Day event

Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases

Wed, 10 Jun 2026 07:30:00 -0400

CLN-978 (CD19 TCE) EULAR data demonstrated potential for immune reset, including remissions, in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA)

CLN-978 data from the first RA multi-dose regimen cohort demonstrated robust efficacy, including clinical remission in a poly-refractory patient, with a favorable safety profile

Initial velinotamig (BCMA TCE) data show promising clinical activity, including complete renal responses in lupus nephritis, supporting potential in plasma cell–driven autoimmune diseases

Complementary T cell engager portfolio unlocks broad commercial opportunity across B cell–driven and autoantibody-mediated diseases

Management to host Immunology Day event

Cullinan Therapeutics reports positive CLN-978 data at EULAR 2026

Sat, 06 Jun 2026 06:33:09 -0400

Cullinan Therapeutics Inc. (NASDAQ: CGEM) presented initial clinical data from Phase 1 studies of CLN-978, a CD19xCD3 T cell engager, at the European Alliance of Associations for Rheumatology Congress. The data was based on 29 patients evaluated across various dose levels in the OUTRACE SLE and RA trials as of May 15, 2026.
In the systemic lupus erythematosus trial, 10 of 14 patients with at least four weeks of follow-up showed a reduction of four points or more in hSLEDAI scores, with five achieving DORIS remission following a single target dose. All laboratory markers of disease activity improved in patients with

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

Sat, 06 Jun 2026 05:15:00 -0400

Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients following a single target dose of CLN-978

Deep, dose-dependent B cell depletion observed in peripheral blood and tissue

Favorable safety profile with single target doses up to 30 µg as well as initial multi-dose regimen

Data from the first RA multi-dose regimen cohort and initial clinical data for velinotamig, a BCMAxCD3 T cell engager, to be shared at Cullinan’s Immunology Day on June 10

CAMBRIDGE, Mass., June 06, 2026 (GLOBE NEWSWIRE) --

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

Sat, 06 Jun 2026 05:15:00 -0400

Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients following a single target dose of CLN-978

Deep, dose-dependent B cell depletion observed in peripheral blood and tissue

Favorable safety profile with single target doses up to 30 µg as well as initial multi-dose regimen

Data from the first RA multi-dose regimen cohort and initial clinical data for velinotamig, a BCMAxCD3 T cell engager, to be shared at Cullinan’s Immunology Day on June 10

CAMBRIDGE, Mass., June 06, 2026 (GLOBE NEWSWIRE) --

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

Sat, 06 Jun 2026 05:15:00 -0400

Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients following a single target dose of CLN-978

Deep, dose-dependent B cell depletion observed in peripheral blood and tissue

Favorable safety profile with single target doses up to 30 µg as well as initial multi-dose regimen

Data from the first RA multi-dose regimen cohort and initial clinical data for velinotamig, a BCMAxCD3 T cell engager, to be shared at Cullinan’s Immunology Day on June 10

CAMBRIDGE, Mass., June 06, 2026 (GLOBE NEWSWIRE) --

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

Sat, 06 Jun 2026 05:15:00 -0400

Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients following a single target dose of CLN-978

Deep, dose-dependent B cell depletion observed in peripheral blood and tissue

Favorable safety profile with single target doses up to 30 µg as well as initial multi-dose regimen

Data from the first RA multi-dose regimen cohort and initial clinical data for velinotamig, a BCMAxCD3 T cell engager, to be shared at Cullinan’s Immunology Day on June 10

CAMBRIDGE, Mass., June 06, 2026 (GLOBE NEWSWIRE) --

Cullinan Therapeutics to Host Immunology Day to Showcase Promising Initial Clinical Data in Autoimmune Diseases for CLN-978, a CD19 T Cell Engager, and Velinotamig, a BCMA T Cell Engager

Tue, 26 May 2026 07:00:00 -0400

New and updated clinical data to be presented from over 30 patients across systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) studies

Initial data from the first multi-dose cohort of RA study to be presented

Initial data from the first multi-dose cohort of velinotamig study also to be shared

Leading key opinion leaders Dr. Ricardo Grieshaber-Bouyer and Dr. John Tesser to share clinical perspectives

The Company will host the in-person event for analysts and institutional investors on Wednesday, June 10, starting at 8:30 a.m. ET in New York City

CAMBRIDGE,

Cullinan Therapeutics to Host Immunology Day to Showcase Promising Initial Clinical Data in Autoimmune Diseases for CLN-978, a CD19 T Cell Engager, and Velinotamig, a BCMA T Cell Engager

Tue, 26 May 2026 07:00:00 -0400

New and updated clinical data to be presented from over 30 patients across systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) studies

Initial data from the first multi-dose cohort of RA study to be presented

Initial data from the first multi-dose cohort of velinotamig study also to be shared

Leading key opinion leaders Dr. Ricardo Grieshaber-Bouyer and Dr. John Tesser to share clinical perspectives

The Company will host the in-person event for analysts and institutional investors on Wednesday, June 10, starting at 8:30 a.m. ET in New York City

CAMBRIDGE,

Cullinan Therapeutics receives FDA orphan drug status for leukemia drug

Tue, 19 May 2026 07:01:00 -0400

Cullinan Therapeutics Inc. (NASDAQ: CGEM) announced that the U.S. Food and Drug Administration granted Orphan Drug Designation to CLN-049 for treating relapsed/refractory acute myeloid leukemia.
CLN-049 is an investigational FLT3xCD3 T cell engager designed to target FLT3-expressing leukemia cells. The drug binds to both mutated and non-mutated FLT3, enabling targeted action regardless of FLT3 mutational status.
The FDA's Orphan Drug Designation applies to drugs intended to treat rare diseases affecting fewer than 200,000 people in the United States. The designation provides development incentives including tax credits for clinical trials, exemption from certain FDA user fees, and potential seven-year market exclusivity following approval.
"FDA

Cullinan Therapeutics receives FDA orphan drug status for leukemia drug

Tue, 19 May 2026 07:01:00 -0400

Cullinan Therapeutics Inc. (NASDAQ: CGEM) announced that the U.S. Food and Drug Administration granted Orphan Drug Designation to CLN-049 for treating relapsed/refractory acute myeloid leukemia.
CLN-049 is an investigational FLT3xCD3 T cell engager designed to target FLT3-expressing leukemia cells. The drug binds to both mutated and non-mutated FLT3, enabling targeted action regardless of FLT3 mutational status.
The FDA's Orphan Drug Designation applies to drugs intended to treat rare diseases affecting fewer than 200,000 people in the United States. The designation provides development incentives including tax credits for clinical trials, exemption from certain FDA user fees, and potential seven-year market exclusivity following approval.
"FDA

Cullinan Therapeutics Receives FDA Orphan Drug Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia

Tue, 19 May 2026 07:00:00 -0400

Orphan Drug Designation underscores the potential of CLN-049, a novel FLT3xCD3 T cell engager, to address significant unmet need in AML

CAMBRIDGE, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to CLN-049, a novel, investigational FLT3xCD3 T cell engager, for the treatment of relapsed/refractory (R/R) acute myeloid leukemia (AML).

“FDA Orphan Drug Designation for CLN-049 emphasizes both the

Cullinan Therapeutics Receives FDA Orphan Drug Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia

Tue, 19 May 2026 07:00:00 -0400

Orphan Drug Designation underscores the potential of CLN-049, a novel FLT3xCD3 T cell engager, to address significant unmet need in AML

CAMBRIDGE, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to CLN-049, a novel, investigational FLT3xCD3 T cell engager, for the treatment of relapsed/refractory (R/R) acute myeloid leukemia (AML).

“FDA Orphan Drug Designation for CLN-049 emphasizes both the

Cullinan Oncology (CGEM) Reiterated at Buy by Stifel on CLN-978 Data

Tue, 19 May 2026 06:51:21 -0400

Stifel analyst Alex Thompson reiterated a Buy rating and $28.00 price target on Cullinan Oncology Inc. (NASDAQ: CGEM).
The analyst commented, "The ABSTRACT for the CLN-978 (CD19xCD3 TCE) data at EULAR on 6/6 was posted. Data with a cut-off of 1/14/26 included 9 SLE and 5 RA patients across 3 cohorts. Details are limited, though note that only GR1 CRS occurred within 24hrs of the 10mcg step up dose with no CRS at a target dose and no ICANs. B-cell depletion appears to trend towards a dose response with trends of clinical activity in both SLE and RA. Of note, no

Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress

Mon, 18 May 2026 17:00:00 -0400

CAMBRIDGE, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and cancer, today announced that initial clinical data from two ongoing Phase 1 studies evaluating CLN-978, a subcutaneously administered CD19xCD3 T cell engager, will be presented at the European Alliance of Associations for Rheumatology (EULAR) European Congress of Rheumatology being held June 3-6, 2026 in London, United Kingdom.

The presentation will feature data from the Phase 1 OUTRACE RA and OUTRACE SLE studies which are evaluating CLN-978

Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress

Mon, 18 May 2026 17:00:00 -0400

CAMBRIDGE, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and cancer, today announced that initial clinical data from two ongoing Phase 1 studies evaluating CLN-978, a subcutaneously administered CD19xCD3 T cell engager, will be presented at the European Alliance of Associations for Rheumatology (EULAR) European Congress of Rheumatology being held June 3-6, 2026 in London, United Kingdom.

The presentation will feature data from the Phase 1 OUTRACE RA and OUTRACE SLE studies which are evaluating CLN-978

Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress

Mon, 18 May 2026 17:00:00 -0400

CAMBRIDGE, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and cancer, today announced that initial clinical data from two ongoing Phase 1 studies evaluating CLN-978, a subcutaneously administered CD19xCD3 T cell engager, will be presented at the European Alliance of Associations for Rheumatology (EULAR) European Congress of Rheumatology being held June 3-6, 2026 in London, United Kingdom.

The presentation will feature data from the Phase 1 OUTRACE RA and OUTRACE SLE studies which are evaluating CLN-978

Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress

Mon, 18 May 2026 17:00:00 -0400

CAMBRIDGE, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and cancer, today announced that initial clinical data from two ongoing Phase 1 studies evaluating CLN-978, a subcutaneously administered CD19xCD3 T cell engager, will be presented at the European Alliance of Associations for Rheumatology (EULAR) European Congress of Rheumatology being held June 3-6, 2026 in London, United Kingdom.

The presentation will feature data from the Phase 1 OUTRACE RA and OUTRACE SLE studies which are evaluating CLN-978

Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress

Mon, 18 May 2026 17:00:00 -0400

CAMBRIDGE, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and cancer, today announced that initial clinical data from two ongoing Phase 1 studies evaluating CLN-978, a subcutaneously administered CD19xCD3 T cell engager, will be presented at the European Alliance of Associations for Rheumatology (EULAR) European Congress of Rheumatology being held June 3-6, 2026 in London, United Kingdom.

The presentation will feature data from the Phase 1 OUTRACE RA and OUTRACE SLE studies which are evaluating CLN-978